Image
ACT 2024 Annual Meeting
17-20 Nov 2024 | Sun, 11/17/2024 - 04:00 Wed, 11/20/2024 - 04:00
November 17-20, 2024 | Austin, Texas | Booth 407
Join Labcorp at the American College of Toxicology
With more than 80 years of toxicology experience, Labcorp is focused on delivering the answers you need to move your program to the next milestone. Our global capacity, flexible scheduling and rapid study initiation creates a streamlined approach to nonclinical services, which means successful design and execution of your program across discovery, safety pharmacology, toxicology, pathology, bioanalytical, and drug metabolism and pharmacokinetics.
Propel Your Development Program with Our Comprehensive Toxicology Solutions
General to specialty
Small and large animal models
All routes of administration
Small and large molecule, cell and gene therapies
Meet our team at ACT
Booth #407
Our commercial and scientific team members will be on-site to provide comprehensive and strategic insights to help reduce risk and move your program more efficiently across critical milestones.
Exhibitor-Hosted Session
Radiopharmaceuticals Drug Development for Oncology: Is my molecule a potential drug?
Radiopharmaceutical development is changing the face of the oncology therapeutic arsenal. This session will review the recent history of regulatory requirements, core elements of study design including technical considerations required to manage the radioisotopes being deployed, investment and merger news, and provide insight into practical experiences managing these programs.
Date: Monday, November 18, 2024
Time: 12:00 PM –12:55 PM
Location: Room #204
Posters
- Assessment of Leading Regulatory T Cell Immunophenotyping Methods using Flow Cytometry
- Development of an Electrochemiluminescence-Based Immunoassay to Evaluate T Cell-Dependent IgG and IgM Responses to Keyhole Limpet Hemocyanin (KLH) Administration in the Juvenile New Zealand White Rabbit
- Comparison of intratracheal and inhaled AAV pulmonary deposition in two species
- Mouse versus Rabbit: Time Course of Corneal Ocular Toxicity of an Antibody Drug Conjugate with a Maytansinoid Payload
- Evaluation of Endogenous and ex vivo Stimulated Matrices for Validation of Cytokine Expression Assessment
- Inhaled delivery of a novel broad spectrum immune modulator to minipigs produces a favorable toxicity profile
- A 29 Day Two Dose and 3 Day One Dose Research and Development Study of Intrathecal Injection or Epidural Infusion in Rats